Related Experiment Video
Updated: May 29, 2025

09:06
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
8.2K
TREM2 as a Therapeutic Target in Atherosclerosis
Siting Xu1, Bo Yang1, Wenhua Yu1
1Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Cell Biology International
|February 1, 2025
Summary
Triggering receptor expressed on myeloid cells-2 (TREM2) is crucial for foamy macrophage survival and atherosclerosis progression. Targeting TREM2 offers a potential therapeutic strategy for treating atherosclerosis.
Area of Science:
- Cardiovascular Research
- Immunology
- Molecular Biology
Background:
- Atherosclerosis involves cholesterol-laden foamy macrophages in arterial walls.
- Single-cell RNA sequencing identified TREM2-high macrophages in atherosclerotic plaques.
- TREM2 plays a key role in foamy macrophage survival and disease progression.
Purpose of the Study:
- To review the role of TREM2 in atherosclerosis.
- To explore TREM2 as a therapeutic target.
- To assess the clinical feasibility of TREM2-based interventions.
Main Methods:
- Literature review of fundamental research on TREM2.
- Analysis of single-cell RNA sequencing data.
- Evaluation of TREM2's therapeutic potential.
Main Results:
- TREM2 is essential for foamy macrophage expansion.
- TREM2 significantly influences atherosclerosis progression.
- TREM2 is a promising therapeutic target.
Conclusions:
- TREM2's role in atherosclerosis is well-established.
- Targeting TREM2 presents a viable therapeutic avenue.
- Clinical application of TREM2 therapies for atherosclerosis is feasible.
Related Concept Videos
Enzyme-linked Receptors
77.1K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.1K
Alzheimer's Disease: Treatment
158
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
158

